Advancing the understanding of venetoclax in t(11;14)-positive multiple myeloma: a comprehensive review of clinical evidence and future prospects

Authors: Abdullah AlZahrani, Nada Alsuhebany, Imran K. Tailor, Abdullah M. Alrajhi

Source: Hematology, Vol 29, Iss 1 (2024)

Subject Terms: Venetoclax, t(11, 14), multiple myeloma, AML, acute myeloid leukemia, BCL2, B-cell lymphoma 2, CAR T-cell, chimeric antigen receptor T-cell, CLL, chronic lymphocytic leukemia, FDA, Food and Drug Administration, IC50, half maximal inhibitory concentration, IL-6: interleukin 6, IMiD, immune-modulators, MM, multiple myeloma, ORR, overall response rate, PFS, progression-free survival, PI, proteasome inhibitor, RRMM, relapsed/refractory multiple myeloma, Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: https://doaj.org/toc/1607-8454

Access URL: https://doaj.org/article/9c59153d5af146aeb7865719eb56c1fe

This result is not displayed to guests.
Login for full access.